Key result
Early clopidogrel noncompliance carries ~2-fold higher risk of death or MI after PCI.
Why the study?
P2Y12 inhibitor non-adherence often occurs and worsens prognosis in ACS, but whether ischemic risk is specifically increased during the early period after clopidogrel noncompliance was unclear.
Does the early period (0 to 90 days) after clopidogrel noncompliance carry a higher risk of death or myocardial infarction compared to the later period (90 to 180 or 90 to 360 days) in patients with acute coronary syndrome?
Meta-Analysis (n=15,326)
Does the early period (0 to 90 days) after clopidogrel noncompliance carry a higher risk of death or myocardial infarction compared to the later period (90 to 180 or 90 to 360 days) in patients with acute coronary syndrome?
In ACS patients, the initial 90 days following clopidogrel noncompliance carries a significantly higher risk of death or MI than the subsequent 90 to 270 days regardless of revascularization or stent type, underscoring the critical need to prevent premature DAPT non-adherence.
Answers are grounded in this paper and cite their sources.
Early nonadherence to clopidogrel in ACS warrants targeted adherence interventions; extends evidence on time-dependent ischemic risk after discontinuation.
Although dual antiplatelet therapy for secondary prevention in acute coronary syndrome (ACS) is highly recommended by current guidelines, P2Y 12 inhibitor non-adherence often occurs and devastates prognosis. To evaluate whether the ischemic risk during the early period of clopidogrel noncompliance was increased among ACS patients, a comprehensive search of PubMed, Embase, and Web of Science was conducted to identify studies reporting early ischemic risk after clopidogrel noncompliance in ACS patients. The primary endpoint was a composite of death or myocardial infarction (MI). Effect sizes were synthesized in patients with or without revascularization. A total of 7 observational studies focusing on clopidogrel noncompliance were included in this meta-analysis, whereas no studies involving ticagrelor or prasugrel were retrieved. A significantly increased risk of death or MI 0 to 90 days after clopidogrel noncompliance was found compared with that during 90 to 180 or 90 to 360 days regardless of revascularization (incidence rate ratio [IRR]: 2.01, 95% confidence interval (CI): 1.62-2.49, P < .001, I 2 = 9%) or not (IRR: 1.61, 95% CI: 1.05-2.48, P < .001, I 2 = 74%). Patients undergoing percutaneous coronary intervention had a higher risk of death or MI 0 to 90 days after clopidogrel noncompliance compared with 90–180 or 90–360 days irrespective of drug-eluting stent or bare metal stent implantation ( P < .05 for both). The early ischemic risk after clopidogrel noncompliance is significantly higher than the late risk in ACS patients. Antiplatelet noncompliance remains a serious concern.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) conducted a meta-analysis in Acute coronary syndrome (ACS) (n=15,326). Early period (0 to 90 days) after clopidogrel noncompliance vs. Late period (90 to 180 or 90 to 360 days) after clopidogrel noncompliance was evaluated on Composite of death or myocardial infarction (MI) in revascularized (PCI) patients (IRR 2.01, 95% CI 1.62-2.49, p=<0.001). Clopidogrel noncompliance within the first 0 to 90 days increased the risk of death or MI compared with 90 to 360 days in ACS patients with PCI and without PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: